Denosumab Found To Be Safer Than Bisphosphonates: No renal toxicity and less hypocalcemia.

PHILADELPHIA — Denosumab, an investigational antibody in phase III studies as a treatment to maintain bone density and cut bone metastases, has so far shown better safety than intravenous bisphosphonates, the main comparator drugs.